Pharmacotherapy in Ventricular Arrhythmias

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Ventricular ectopy, including premature ventricular contractions and ventricular tachycardia, is common and arises from various mechanisms like reentry and automaticity.
• Scar-based reentry is a primary cause of malignant ventricular arrhythmias (VA) leading to sudden cardiac death.
• Antiarrhythmic drugs, classified by Vaughan Williams Singh, target different phases of the cardiac action potential to suppress VA.

Purpose of the Study:

• To review the current role and applications of antiarrhythmic agents in managing ventricular arrhythmias.
• To highlight the efficacy and limitations of different antiarrhythmic drug classes.
• To discuss the evolving landscape of VA management with new technologies.

Main Methods:

• Review of existing literature on antiarrhythmic drug mechanisms, classifications, and clinical applications.
• Analysis of the benefits and contraindications of specific antiarrhythmic agents like Class Ic drugs, beta-blockers, and amiodarone.
• Discussion of emerging technologies in cardiac imaging and artificial intelligence for risk stratification.

Main Results:

• Class Ic agents are effective for premature ventricular contraction suppression but contraindicated in certain cardiac conditions.
• Beta-blockers are a primary treatment for symptomatic VA, well-tolerated, and beneficial in coronary heart disease and systolic dysfunction.
• Amiodarone is effective for severe VA, especially in acute settings, but has significant long-term toxicity concerns.

Conclusions:

• Antiarrhythmic agents remain vital for suppressing various ventricular arrhythmias, including channelopathies and polymorphic VT.
• Judicious use of antiarrhythmics, with careful attention to side effects, can mitigate long-term cardiac dysfunction.
• Advancements in cardiac imaging and AI offer future potential for improved risk assessment and personalized pharmacological management of VA.